3540 C.I. MEDICAL CO.,LTD. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

3540

TSE Standard

C.I. MEDICAL CO.,LTD.

967

JPY

(0.00%)

Dec 23, 3:30 pm JST

6.17

USD

Dec 23, 1:30 am EST

Result

PTS

outside of trading hours

ー

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2020	37,393	4,702	4,773	2,920	58.4	11.68	Feb 12, 2021	J-GAAP
Dec, 2021	41,205	4,523	4,605	2,820	56.4	5.64	Feb 10, 2022	J-GAAP
Dec, 2022	42,891	3,990	3,889	2,521	50.4	5.04	Feb 14, 2023	J-GAAP
Dec, 2023	45,628	2,989	3,295	2,082	41.7	5.04	Feb 13, 2024	J-GAAP
Dec, 2024 Guidance	67,553	2,349	2,475	6,130	122.6	－	Nov 7, 2024	J-GAAP
YoY	+48.1%	-21.4%	-24.9%	+194.4%	+194.4%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Dec, 2019	Feb 12, 2019	28,392	2,060	2,092	1,455	－	J-GAAP
- Results	Feb 13, 2020	28,763	2,100	2,141	1,505	3.01	J-GAAP
Dec, 2020	Feb 13, 2020	Available in future release
	Oct 20, 2020
	Jan 26, 2021
Results	Feb 12, 2021
Dec, 2021	Feb 12, 2021
Results	Feb 10, 2022
Dec, 2022	Feb 10, 2022
Results	Feb 14, 2023
Dec, 2023	Feb 14, 2023
Results	Feb 13, 2024
Dec, 2024	Feb 13, 2024	50,000	3,528	3,620	2,447	－*	J-GAAP
-	Nov 7, 2024	67,553	2,349	2,475	6,130	－*	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Dec, 2012	10,947	－	Available in future release
Dec, 2013	13,236	+20.9
Dec, 2014	15,926	+20.3
Dec, 2015	18,145	+13.9
Dec, 2016	20,334	+12.1
Dec, 2017	22,830	+12.3
Dec, 2018	25,806	+13.0
Dec, 2019	28,763	+11.5
Dec, 2020	37,393	+30.0
Dec, 2021	41,205	+10.2
Dec, 2022	42,891	+4.1
Dec, 2023	45,628	+6.4
Dec, 2024 Guidance	67,553	+48.1	2,349	-21.4	2,475	-24.9	122.6	+194.0

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Dec, 2022	42,891	3,990	9.30	14.75	10.06	1.71	50.4
Dec, 2023	45,628	2,989	6.55	10.88	5.81	1.27	41.7
Dec, 2024 Guidance	67,553	2,349	3.48	24.46	10.55	1.16	122.6

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	45,628	4,702	4,773	2,920	58.4
Fiscal Year	Dec, 2023	Dec, 2020	Dec, 2020	Dec, 2020	Dec, 2020

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jul - Dec, 2021	20,791	1,977	2,002	1,270	25.4	5.64	Feb 10, 2022	J-GAAP
Jul - Dec, 2022	21,928	1,665	1,556	993	19.9	5.04	Feb 14, 2023	J-GAAP
Jul - Dec, 2023	23,431	1,221	1,342	856	17.1	5.04	Feb 13, 2024	J-GAAP
Jul - Dec, 2024 Guidance	43,237	1,366	1,504	5,553	111.1	－	Nov 7, 2024	J-GAAP
YoY	+84.5%	+11.9%	+12.1%	+548.7%	+548.7%

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Dec, 2021	4,523	-1,473	1,578	-3,051	-584	3,649	18.32	J-GAAP
Dec, 2022	3,990	-8,640	1,409	-10,049	6,710	1,731	5.73	J-GAAP
Dec, 2023	2,989	-9,951	-156	-9,795	9,825	1,698	4.09	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 3rd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Jan - Sep, 2022	31,468	3,174	3,214	2,098	42.0	82.6	Nov 8, 2022	J-GAAP
Jan - Sep, 2023	33,648	2,548	2,752	1,739	34.8	83.5	Nov 13, 2023	J-GAAP
Jan - Sep, 2024	45,248	1,108	1,285	5,337	106.8	51.9	Nov 12, 2024	J-GAAP
YoY	+34.5%	-56.5%	-53.3%	+206.9%	+206.8%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2022	11,423	816	675	423	8.5	7.1	Feb 14, 2023	J-GAAP
Jan - Mar, 2023	10,999	786	851	521	10.4	7.1	May 9, 2023	J-GAAP
Apr - Jun, 2023	11,198	982	1,102	705	14.1	8.8	Aug 8, 2023	J-GAAP
Jul - Sep, 2023	11,451	780	799	513	10.3	6.8	Nov 13, 2023	J-GAAP
Oct - Dec, 2023	11,980	441	543	343	6.9	3.7	Feb 13, 2024	J-GAAP
Jan - Mar, 2024	11,946	407	407	247	5.0	3.4	May 14, 2024	J-GAAP
Apr - Jun, 2024	12,370	576	564	330	6.6	4.7	Aug 13, 2024	J-GAAP
Jul - Sep, 2024	20,932	125	314	4,760	95.2	0.6	Nov 12, 2024	J-GAAP
YoY	+82.8%	-84.0%	-60.7%	+827.9%	+828.0%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Oct - Dec, 2019	6,758	-1.6	Available in future release
Jan - Mar, 2020	8,280	+22.2
Apr - Jun, 2020	8,694	+24.3
Jul - Sep, 2020	9,519	+15.6
Oct - Dec, 2020	10,900	+61.3
Jan - Mar, 2021	10,480	+26.6
Apr - Jun, 2021	9,934	+14.3
Jul - Sep, 2021	10,186	+7.0
Oct - Dec, 2021	10,605	-2.7
Jan - Mar, 2022	10,417	-0.6
Apr - Jun, 2022	10,546	+6.2
Jul - Sep, 2022	10,505	+3.1
Oct - Dec, 2022	11,423	+7.7
Jan - Mar, 2023	10,999	+5.6
Apr - Jun, 2023	11,198	+6.2
Jul - Sep, 2023	11,451	+9.0
Oct - Dec, 2023	11,980	+4.9
Jan - Mar, 2024	11,946	+8.6
Apr - Jun, 2024	12,370	+10.5
Jul - Sep, 2024	20,932	+82.8	125	-84.0	314	-60.7	95.2	+824.3

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	20,932	1,633	1,659	4,760	95.2
Fiscal Year	Sep, 2024	Dec, 2020	Dec, 2020	Sep, 2024	Sep, 2024

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Dec, 2021	1,597.77	80.2	19,915	15,977	16,009	ー	Feb 10, 2022	J-GAAP
Dec, 2022	1,821.65	60.3	30,186	18,216	18,249	0.39	Feb 14, 2023	J-GAAP
Dec, 2023	2,005.86	48.3	41,506	20,058	20,079	0.86	Feb 13, 2024	J-GAAP
Jan - Sep, 2024	ー	43.1	58,107	25,060	25,164	0.77	Nov 12, 2024	J-GAAP

C.I. MEDICAL CO.,LTD.(3540) Financial Results